

Now enrolling: The ARIA study for adolescents with asthma




The ARIA study is evaluating an inhaled study drug that consists of a combination of 3 medicines. This combination of medicines is currently approved in several countries as the first once-daily, single-inhaler, triple therapy for the maintenance treatment of asthma in adults.

To be eligible for this study, participants must be*:

- 12 to 17 years of age
- Diagnosed with asthma for at least 1 year
- Currently taking certain medications for asthma

*Not a complete list of eligibility criteria



The study sponsor, GSK, is committed to ensuring clinical study participants are representative of the population affected by asthma.

To learn more about the ARIA study, contact your local study site:

[site contact information]

GSK

